Global AI in Diagnostics Market Soars with USD 1,621 Mn in 2024, Projected to Reach USD 4,829 Mn by 2030 at 19.95 % CAGR

The global AI in Diagnostics market is valued at USD 1,621 million in 2024, with robust growth projected through the forecast period. Leading industry figures anticipate a CAGR of approximately 19.95 % from 2024 to 2030, pushing the market size to USD 4,829 million by 2030 This surge is fueled by widespread integration of AI-driven diagnostic tools across neurology, cardiology, oncology, and imaging – with North America currently commanding the largest share of over 57 % .

AI in Diagnostics Market Highlights & Analysis

• Rapid adoption across specialties: AI diagnostic solutions are increasingly used in neurology, radiology, oncology, cardiology, and pathology, enhancing accuracy and workflow efficiency .
• Chronic disease burden: Growth in chronic and non-communicable diseases worldwide amplifies demand for early detection through AI-enabled diagnostics
• Skilled professional shortage: With a shortage of radiologists and diagnostic experts, AI-powered tools are bridging the gap to ensure faster and more accurate results
• Government initiatives & regulation: Nations like the U.S. and Canada are accelerating AI adoption through regulatory frameworks, healthcare innovation grants, and public–private partnerships.
• Technological advancements: Advances in ML, DL, and NLP are enabling improved interpretation of imaging and neurological data, fueling adoption in complex diagnoses

Key Takeaways from the Market Research Report

• Increasing prevalence of chronic and neurological diseases
• Integration of AI to address professional shortages and improve diagnostic accuracy
• Continued government support via innovation programmes
• Expansion across multiple medical domains, including oncology & imaging
• Rising availability of AI-powered platforms and cloud-based services

AI in Diagnostics Market Major Players Driving Innovation

• Siemens Healthineers
• Nanox Imaging Ltd.
• Riverain Technologies
• Vuno, Inc.
• Aidoc
• Neural Analytics
• Imagen Technologies
• Digital Diagnostics, Inc.
• GE Healthcare
• AliveCor Inc.
• Enlitic
• InformAI
• Nvidia Corporation
• Advanced Micro Devices, Inc.
• Koninklijke Philips N.V.

 AI in Diagnostics Market Segmentation Analysis

By Component

• Hardware
• Software
• Services

By Modality

• Imaging Modalities
• Computed Tomography
• X-Ray
• Ultrasound
• Mammography
• Others
• Diagnostics Modalities
• Immunoassay
• Clinical Chemistry
• Microbiology
• Others

By Application

• Cardiology
• Oncology
• Pathology
• Radiology
• Chest and Lung
• Neurology
• Others

By End User

• Hospitals
• Diagnostic Imaging Centers
• Diagnostic Laboratories
• Others

Highlighted Driver: Neurology AI Solutions

Artificial Intelligence’s role in neurological diagnostics is gaining momentum. Advanced ML and DL tools are being used to analyze complex data—such as MRI, CT scans, and patient history—to support early identification of neurological disorders. This is especially significant in regions with scarce specialist access. Neurology-focused AI software not only aids clinicians in timely disease detection but also facilitates personalized care plans based on early biomarkers and genomic insights, ensuring patients receive targeted treatment faster. The result: reduced misdiagnoses and improved patient outcomes.

Leading Segment: Imaging Diagnostics

The AI-enabled Medical Imaging segment dominates the diagnostics market. Valued at USD 3.23 billion in 2023 and expected to reach USD 16.20 billion by 2030, it is set to grow at a CAGR of 25.9 % This growth stems from CT, MRI, and X-ray applications where AI automates image analysis, flags abnormalities, and speeds up diagnoses. With a shortage of radiologists, AI platforms offer time-saving benefits, while also integrating seamlessly with existing hospital systems to support workflow efficiency and decision-making.

Regional Insights

North America remains the powerhouse of the AI diagnostics market, commanding over 57 % share thanks to advanced healthcare infrastructure and tech-friendly regulation

Europe is rapidly adopting AI, with strong R&D in Germany, the UK, and France.

Asia-Pacific, particularly India and China, is emerging fast—boosted by public health initiatives, growing private investments, and a high disease burden.

Regional spotlight: Ontario, Canada, serves as a biotech and AI innovation hub, with government demo programs that accelerate real-world clinical validation and deployment.

Future Outlook

With these dynamic trends, the industry is projected to grow and expand during 2025–30 as the above-stated factors reshape the market landscape and open opportunities for players. Market participants can enhance their market size and revenue by adapting to evolving dynamics and customer expectations. Furthermore, by leveraging SWOT analysis, companies can realign capabilities to emerging trends—ultimately augmenting global industry size and volume.